id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-293646-d4qcckh1	Meanwell, Nicholas A.	Chapter 22. Non-HIV antiviral agents	2003-12-31		.txt	text/plain	4178	198	46	The first small molecule inhibitor of Hepatitis C Virus (HCV), the NS3 protease inhibitor BILN-2061, entered phase 2 clinical trials, producing a striking reduction in viral load in treated individuals. Inhibitors of Hepatitis B Virus (HBV) -Adefovir dipivoxil iHepsera'") (1) was approved in the US for the treatment of HBV on September 20', 2002 and in the European Union on March 1 lth, 2003, providing a second small molecule antiviral to add to lamivudine (3TC) and the injectable protein IFNa as the only approved agents for treating HBV infection. Pyridinedicarboxamide S represents the first report of a non-nucleoside inhibitor of HBV reverse transcriptase enantiomer of q is active in cell culture and appears to prevent proper formation of the viral nucleocapsrd. A significant advance towards establishing a correlation between replicon inhibition and clinical efficacy was recently accomplished with the disclosure of preliminary clinical data for BILN-2061, a selective inhibitor of the NS3 serine protease of HCV that is structurally related to 13.	./cache/cord-293646-d4qcckh1.txt	./txt/cord-293646-d4qcckh1.txt